De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer

MLA

Alex K. Bryant, et al. “De-Escalating Adjuvant Durvalumab Treatment Duration in Stage III Non-Small Cell Lung Cancer.” European Journal of Cancer, vol. 171, Aug. 2022, pp. 55–63. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1a906c9556261cc9fd4c869c35638df8&authtype=sso&custid=ns315887.

APA

Alex K. Bryant, Kamya Sankar, Lili Zhao, Garth W. Strohbehn, David Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath, & Michael D. Green. (2022). De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. European Journal of Cancer, 171, 55–63.

Chicago

Alex K. Bryant, Kamya Sankar, Lili Zhao, Garth W. Strohbehn, David Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath, and Michael D. Green. 2022. “De-Escalating Adjuvant Durvalumab Treatment Duration in Stage III Non-Small Cell Lung Cancer.” European Journal of Cancer 171 (August): 55–63. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1a906c9556261cc9fd4c869c35638df8&authtype=sso&custid=ns315887.